Literature DB >> 11142760

FRAXA screening in Brazilian institutionalized individuals with nonspecific severe mental retardation.

M V Mulatinho1, J C Llerena, M M Pimentel.   

Abstract

Individuals with mental disabilities are a heterogeneous group, mainly when we consider the etiology of mental retardation (MR). Recent advances in molecular genetics techniques have enabled us to unveil more about the molecular basis of several genetic syndromes associated with MR. In this study, we surveyed 85 institutionalized individuals with severe MR, 38 males and 47 females, by two molecular techniques, to detect CGG amplifications in the FMR1 gene. No FRAXA mutations were found in the FMR1 gene, reinforcing the low prevalence of Fragile X syndrome among institutionalized individuals with severe MR. We considered the PCR protocol used adequate for screening males with mental retardation of unknown etiology. The use of the Southern blot is still necessary for the decisive diagnosis of the Fragile X syndrome. To exclude chromosomal abnormalities associated with MR as a possible cause of the phenotype in these individuals, G-banded chromosome analysis was performed in all patients and 7.3% of chromosomal aberrations were found. Our results are similar to those reported previously and point to the necessity of expanding the molecular investigation toward other causes of MR, such as subtle chromosomal rearrangements, as suggested recent by a combination of fluorescence in situ hybridization (FISH) and PCR studies.

Entities:  

Mesh:

Year:  2000        PMID: 11142760     DOI: 10.1089/10906570050501515

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  2 in total

Review 1.  Fragile X syndrome: the FMR1 CGG repeat distribution among world populations.

Authors:  Emmanuel Peprah
Journal:  Ann Hum Genet       Date:  2011-12-21       Impact factor: 1.670

Review 2.  FMR1 and the fragile X syndrome: human genome epidemiology review.

Authors:  D C Crawford; J M Acuña; S L Sherman
Journal:  Genet Med       Date:  2001 Sep-Oct       Impact factor: 8.822

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.